Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT05289674
Other study ID # J number
Secondary ID
Status Completed
Phase N/A
First received
Last updated
Start date October 4, 2021
Est. completion date June 30, 2022

Study information

Verified date October 2022
Source Universitas Airlangga
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

Lactoferrin is an iron-binding glycoprotein of the transferrin family which is expressed and refers to it as a "red protein from milk". It is known that lactoferrin can modulate the overall immune response in inflammatory disorders including modulation of cytokine/ chemokine production and immune regulation that resenting by interleukin (IL)-10. Children with failure to thrive have increase the risk of infectious disease. The mechanism behind this may be due to impaired of immune function, in which pro-inflammation response is increased (IL-1β, IL-6), while IL-10 acted as anti-inflammation response tends to reduces. High calorie formula (Oral Nutrition Supplement/ONS) are products used for oral nutrition support with the aim of increasing nutritional intake. they are a nutrition treatment option for when nutrition support has been identified beside dietary counselling. ONS are typically used in addition to a normal diet, when diet alone is insufficient to meet daily nutritional requirement due to infection or others. ONS should be treated like medication, ensure they are labelled with the patient's name and provided at the prescribed time. It is well established that nutritional deficiency or inadequate can impair immune function. Growing evidence suggest that for certain nutrients increased intake above currently recommended levels may help optimize immune function including improving the defense function and thus resistance to infection while maintaining tolerance. This study aims to analize the levels of IL-6 and IL- 10 in children with failure to thrive with infection before and after receiving the intervention of lactoferrin in high-calorie formula milk. This study is an observational study with a pre-, post-test design, with designed total subject is 80. The subject is healthy children with weight faltering aged 1-5 years diagnosed with infection (tuberculosis/TB or urinary tract infection/UTI)


Description:

Interventional study with a pre-, post-test design. After the subject were diagnosed with infection (tuberculosis/TB or urinary tract infection/ UTI), they will receive 400 kcal/day (96 g/day divided 4 times consumption) of high calorie formula prescribed by the researcher (A pediatrician) for 90 days consumption (8640 g). the subject will monitored every 30 days for acceptance, tolerance, weight increment, length increment evaluation. The blood will be withdrawn at day 0 (before invention) and day 90 (after intervention) to measure the IL-6 and IL-10 levels. The high calorie formula is given as much as 400 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis will be determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia


Recruitment information / eligibility

Status Completed
Enrollment 75
Est. completion date June 30, 2022
Est. primary completion date June 30, 2022
Accepts healthy volunteers No
Gender All
Age group 1 Year to 5 Years
Eligibility Inclusion Criteria: • Children aged 1 - 5 years were diagnosed with failure to thrive with infections (TB or UTI) Exclusion Criteria: - Fluid retention - Organomegaly - Tumor mass - Congenital abnormalities - Cerebral Palsy - Hormonal disorders and syndrome Drop out Criteria: • Lost contact

Study Design


Related Conditions & MeSH terms


Intervention

Dietary Supplement:
High Calorie Formula
The high calorie formula is given as much as 300 kcal/day for 90 days after the subject were diagnosed with tuberculosis (TB) or urinary tract infection (UTI), determine as day 1. the diagnosis were determined by pediatrician. Before the intervention (day 0) and after the intervention (day 61), the subjects were taken the blood by laboratory employee of the private hospital in Surabaya, Indonesia

Locations

Country Name City State
Indonesia Husada Utama Hospital Surabaya East Java

Sponsors (2)

Lead Sponsor Collaborator
Universitas Airlangga Danone Institute International

Country where clinical trial is conducted

Indonesia, 

Outcome

Type Measure Description Time frame Safety issue
Primary Acceptance and tolerance of high calorie formula by the subject Change on IL-6 levels (in ng/mL), the data will be presented as mean +/- SD. The level of IL-6 will be investigated using human IL-6 ELISA kit (BT Lab) 90 days
Primary Acceptance and tolerance of high calorie formula by the subject Change on IL-10 (in ng/mL), the data will be presented as mean +/- SD. The level of IL-10 will be investigated using human IL-10 ELISA kit (BT Lab) 90 days
Secondary Acceptance and tolerance of high calorie formula by the subject Change on body weight (in kg) the data will be presented as mean +/- SD.The body weight will be measure using digital baby scale (Seca 354) and digital scale Seca Robusta 813. 90 days
Secondary Acceptance and tolerance of high calorie formula by the subject Change on body length/body height (in cm). The body length/height will be measure using infantometer (Seca 416) and stadiometer (for children aged < 2 years, Seca 213) 90 days
See also
  Status Clinical Trial Phase
Recruiting NCT06055777 - Study of the Safety, Tolerability, and PK of SZEY-2108 Administered Intravenously to HVs in SAD and MAD Cohorts Phase 1
Recruiting NCT05793983 - S100A8/A9 and Innate Immunity in Liver Disease
Active, not recruiting NCT05963269 - The Effect of the Game on Students' Intramuscular Injection Skills N/A
Not yet recruiting NCT02222779 - Quantification of Transition Metals N/A
Completed NCT01976234 - Stored RBC Transfusion and Immonomodulation N/A
Completed NCT01530763 - Safety and Efficacy Study of Ceftaroline Versus a Comparator in Pediatric Subjects With Community Acquired Bacterial Pneumonia (CABP) Phase 2/Phase 3
Completed NCT02345135 - Susceptibility to Infections in Ataxia Telangiectasia N/A
Completed NCT01158560 - A Trial of Vitamin D and Health Advice for the Prevention of Upper Respiratory Tract Infections Phase 3
Completed NCT01176786 - Reusable Versus Disposable Draping System in Breast Reconstruction Surgery N/A
Active, not recruiting NCT05284097 - Ad26.ZEBOV, MVA-BN-Filo Vaccination in Children and Adults Previously Vaccinated With Control in the EBOVAC-Salone Study Phase 2
Enrolling by invitation NCT06055712 - Antibiotic Prophylaxis in Pediatric Open Fractures Phase 4
Not yet recruiting NCT06338345 - Pharmacokinetics and Modelling of Beta-Lactam in ECMO-VA Patients N/A
Recruiting NCT06002685 - Partners in Children's Health (CSN): A Randomized Trial of an Attachment Based Intervention N/A
Completed NCT02802059 - E. Coli Nissle 1917 - Suspension for Infection Prophylaxis Phase 3
Recruiting NCT05770765 - Creation of a Bank of Biological Materials and Associated Data Related to Patients With Infectious and Tropical Diseases
Completed NCT05389540 - Rural South and Southeast Asia Household Health Survey
Completed NCT05080920 - Rosmalip® for Cancer Infections Prevention N/A
Recruiting NCT05287438 - Next Generation Sequencing Versus Traditional Cultures for Clinically Infected Penile Implants: Impact of Culture Identification on Outcomes N/A
Recruiting NCT05610098 - Gene Expression Profiles in Spinal Tuberculosis.
Recruiting NCT06178822 - Towards Novel BIOmarkers to Diagnose SEPsis on the Emergency Room